The latest thought leadership from our expert teams

Active filters (1)
Bioprocessing engineering - digital twins in cultured protein scale up
Opinion

How digital twins can help confront the challenges of scaling up cultured protein

9th Mar 2023

In the world of bioprocessing engineering, companies developing cultured meat and other cultured ingredients face both technical and financial challenges at each step up in scale. Here, Steve Thomas and James Westley explain how sophisticated predictive models – digital twins – that couple biology, heat transfer, mass transfer and fluid dynamics can help… 

  • AI & Analytics
  • Bioinnovation
  • Digital service innovation
  • Fluids & thermodynamics
  • Synthetic biology
Bioprocessing meets machine learning
Opinion

Bioprocessing meets machine learning: the conversation that is driving a cell therapy breakthrough

8th Mar 2023

A meeting of minds - AI meets biology. This is the conversation that is bridging the gap between bioprocessing and machine learning.

  • AI & Analytics
  • Bioinnovation
  • Cell and gene therapy
  • Synthetic biology
Quantum for pharma
Opinion

Quantum computing for pharma and life sciences – opportunities are on the horizon

21st Feb 2023

What can quantum computing and quantum technology do for the pharma and life sciences industry? After reviewing the latest signs of quantum innovation in practice across Europe, Elizabeth Thomas has conferred with Cambridge Consultants’ quantum experts and now shares her insights into how organisations can start implementing an action plan… 

  • AI & Analytics
  • Physical sciences
  • Strategic advice
  • Synthetic biology
biological cells
Opinion

How ‘cell mechanomics’ can empower drug discoveries, cell therapies and precision cancer medicine

7th Sep 2022

Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. It is a biomarker that Cell4D is using to screen and sort live cells

  • Bioinnovation
  • Cell and gene therapy
  • Synthetic biology
start-up risk assessment
Opinion

Start-up technology can be risky business if threats aren’t tackled hard and early

19th Aug 2022

Founders of early-stage start-ups are characteristically passionate, driven and optimistic. Understandably so. Very often they are nurturing a breakthrough idea with the capacity to disrupt business and change the world for the better. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong. 

  • AI & Analytics
  • Bioinnovation
  • Cell and gene therapy
  • Connectivity & IoT
  • Innovation management
  • Project management
  • Robotics
  • Strategic advice
  • Sustainability
  • Synthetic biology
Medtech Innovator APAC 2022
Opinion

MedTech Innovator is not a one-off, start-up nurturing is in our DNA

16th Aug 2022

Yan Lin Lye and a team from CC are embarking on a sequence of mentoring sessions as part of our commitment to MedTech Innovator Asia Pacific. For the second consecutive year, we're collaborating with the organisation to provide hands-on professional support to selected start-up participants.

  • Bioinnovation
  • Cell and gene therapy
  • Strategic advice
  • Synthetic biology
Biotech
Opinion

From glowing flowers to decomposing buildings – it was an illuminating week for biotech in the Bay Area

17th May 2022

From almost three years of pandemic restrictions to a three-day biology bonanza. Senior Biomedical Engineer Ellen Simmons gets back on the live conference trail with a visit to Built With Biology, formerly SynBioBeta. Here she shares her experiences – and enthusiasm for helping to drive the biotech ecosystem forwards… 

  • Bioinnovation
  • Sustainability
  • Synthetic biology